Cutaneous T-cell lymphoma (CTCL) represents a category of complex and diverse disease states that involve the skin as the primary site of malignant T-lymphocyte proliferation and is a type of non-Hodgkin lymphoma. These malignant CD4+ T cells (lymphocytes) also can invade the lymphatic nodes, blood, and visceral organs. Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are the most common types of CTCL. These chronic diseases are rare and have considerable variation in cutaneous presentation, histologic appearance, degree of blood involvement, immunophenotypic profile, and prognosis.
Historically, the French were pioneers in the discovery of CTCL. Approximately 200 years ago, Jean Louise Alibert published an article describing the appearance of tumors on the skin similar to that of a mushroom and coined the term mycosis fungoides (Alibert, 1806). In 1938, French physicians Sézary and Bouvrain published the discovery of an atypical T lymphocyte in the blood of a patient who had skin findings that were consistent with MF and who was erythrodermic at the same time. Further advances in cutaneous lymphomas continued in the 20th century with the discoveries of cutaneous B-cell, natural killer cell, and gamma delta-cell lymphomas, as well as variants of MF. In the mid-1970s, Edelson and Lutzner coined the term CTCL to unify all the diagnoses recognized as cancer that shared a common T-cell phenotype including MF and SS (Lutzner et al., 1975). The term CTCL should not be used interchangeably with MF and SS; rather, it should be used only to describe the complete spectrum of cutaneous lymphomas of T-cell origin.
The World Health Organization and the European Organisation for Research and Treatment of Cancer met in 2003 and 2004 to organize and define the cutaneous lymphomas and to separate them from systemic lymphomas with similar histology (Willemze et al., 2005). Lymphomas are now classified as either T-cell or B-cell lymphoma with indolent, intermediate, or aggressive clinical behavior, allowing for more consistent diagnosis and treatment regimens (see Figure 4-1).
MF and SS are rare diseases despite evidence that their prevalence is increasing. Utilizing the National Cancer Institute's Surveillance, Epidemiology, and End Results data, Criscione and Weinstock (2007) reported that the incidence of CTCL tripled to 6.4 per million from 1973 to 2002 in the United States, with a 2.9-per-million increase per decade over the same period. This increased incidence may be a result of better medical awareness and screening methods. CTCL occurs 32% more often in blacks than in whites, and the ratio of male to female is 2:1 with an increase in incidence with age. CTCL in children is confirmed but uncommon. MF was found to be responsible for 72% of all CTCL cases, and SS represented 2.5% of all CTCLs. Overall, CTCL represents 3.9% of all non-Hodgkin lymphomas, with substantial geographic variation in incidence. An increased incidence is found in areas with high physician density, high family income, higher education, and high home property values. These findings may represent a difference in access to medical care and, thus, earlier or better diagnosis. Nurses should be alert to the potential for opportunities for patient/community education about CTCL. Given the evidence of an increasing incidence of CTCL, dermatology and oncology nurses must remain apprised of the latest literature on accurate detection and treatment of CTCL.
The cause of MF and SS (as well as other CTCLs) is unknown. Infectious agents, including bacteria and viruses, have been proposed as possible triggers for CTCL (Hwang, Janik, Jaffe, & Wilson, 2008). Herne, Talpur, Breuer-McHam, Champlin, and Duvic (2003) associated cytomegalovirus infection with CTCL, and Chang, Liu, Chen, and Chow (1998) detected the Epstein-Barr virus in patients with T-cell lymphomas of the skin. Although these associations are intriguing, the data are not strong enough to conclude that a causal relation exists. However, the quest to find the etiology of MF and SS has led to a great increase in information available about the genetic and immune abnormalities found in MF and SS. Ultimately, understanding the pathophysiology of MF and SS may help in the development of novel therapies to treat these lymphoid malignancies (Hwang et al.).
The pathology of MF and SS is characterized by neoplastic CD4+ T cells that preferentially home to migrate and expand in the skin. CD4+ T cells help to regulate the generation of T-cell-mediated responses, which are functionally mediated by another class of T cells that express the surface protein CD8+. Generally, the malignant T cells in MF and SS show signs of activation, releasing cytokines and other proteins that cause the skin cells (keratinocytes) to proliferate, leading to scaling and thickening of the epidermis characteristic of these diseases. These cytokines, including interleukin (IL)-4, may contribute to the mild-to-moderate immunosuppression that may be present in patients with MF and SS. Moreover, the release of cytokines may contribute to the pruritus that is present in many patients at all stages of MF and SS. In the patch and plaque stages of the disease, malignant T cells represent a relatively small proportion of total T cells in the skin because normal T cells, including those of the CD8+ phenotype, often are present as a "reaction" to the malignant T cells. When patients develop thick plaques and tumors, the majority of the T cells in these lesions are derived from the malignant clone (Girardi, Heald, & Wilson, 2004). Hwang et al. (2008) proposed that multiple abnormalities in the immune environment in the skin, including the antigen-presenting cells (also known as dendritic cells) that stimulate T cells, contribute to the clinical signs and symptoms of MF and SS.
Malignant CD4+ MF and Sézary cells generally express the CD45RO surface protein marker, which identifies these cells as "memory" T cells that have previously been activated by antigen. This marker differentiates these cells from CD45RA+ T cells that are "naïve" and have not yet been stimulated to proliferate by antigen. Memory T cells have an enhanced ability to proliferate and to secrete cytokines, even in the presence of small amounts of antigen presented by antigen-presenting cells. Memory T cells are proficient at migrating from the blood to inflamed tissue, including skin, because they express specific chemotactic receptors known as chemokine receptors and adhesion molecules (Sallusto, Lenig, Forster, Lipp, & Lanzavecchia, 1999). Evidence exists that CD45RO+ tumor cells in patients with MF may escape immune recognition and destruction through expression of proteins that potentially induce apoptosis of antitumor, cytotoxic CD8+ T cells, which may otherwise control the malignant T cells (Ni, Hazarika, Zhang, Talpur, & Duvic, 2001).
Alterations in specific cytokines and chemokines (small chemotactic proteins) have been proposed to contribute to clonal expansion and immunosuppression in MF and SS (Yamanaka et al., 2006b). IL-18 expression may play a role in the immunosuppression that is characteristic of late-stage CTCL (Yamanaka et al., 2006a). IL-15, which requires presentation by antigen-presenting cells, may contribute to T-cell proliferation (Dooms et al., 1998). IL-4 and IL-5, which skew the immune environment, can lead toward a humoral (antibody-mediated) Th2-type immune response (Vowels et al., 1994). Additionally, chemokines may play a role in attracting malignant T cells to the skin and enhancing their ability to survive by acting upon G-protein-coupled chemokine receptors found on the surface of T cells (Clark et al., 2006; Notohamiprodjo et al., 2005; Sokolowska-Wojdylo et al., 2005).
Edelson (2001) hypothesized that the survival and proliferation of the neoplastic T cells in MF and SS were enhanced by antigen-presenting dendritic cells based on evidence that dendritic cells support the long-term culture of SS cells. Interestingly, skin dendritic cells known as Langerhans cells frequently localize in the epidermis adjacent to malignant T cells in MF, creating the so-called Pautrier abscess, an often-observed histologic sign of MF (see Figure 4-2).
Recent evidence suggests that MF, even in its early stages, may be a systemic disease. In normal individuals, the T-cell receptor varies tremendously among different T cells for these cells to bind hundreds of thousands of potential antigens. The normal T-cell repertoire in humans is diverse and large. Yawalkar et al. (2003) recently reported the loss of normal T-cell repertoire in all stages of MF and SS, a finding that may have a relationship to the origin of these diseases. The loss of normal T-cell repertoire is a phenomenon that has been observed after infection with certain viruses, including HIV-1. Hwang et al. (2008) have speculated that MF may arise from continued (chronic) reactivity of malignant T cells to normal skin antigens following initial infection with a yet-undefined virus.
In summary, although the etiologies of MF and SS remain unknown, multiple abnormalities in cytokine expression, chemokine expression, and antigen presentation have been revealed. Together, these abnormalities may contribute to the immunosuppression seen in MF, particularly in the late stages, or in SS. Therapies that target these abnormalities are beginning to show positive benefits in the treatment of MF and SS.
The most common staging system in use for CTCL was created in 1978 at a National Cancer Institute Workshop on CTCL (Lamberg & Bunn, 1979). Subsequently, the International Society for Cutaneous Lymphoma updated the criteria for blood involvement to distinguish among three subsets of erythrodermic CTCL (E-CTCL). The subsets include SS as leukemic phase E-CTCL, erythrodermic MF as secondary E-CTCL, and E-CTCL as not otherwise defined (Vonderheid et al., 2002). The leukemic criteria of SS are intended to differentiate these patients with a poorer prognosis from the other E-CTCL subsets. The leukemic criteria are further explained under SS in Patient Assessment.
The MF staging system employs a multistep process. Because the malignant T cells can traffic among skin, lymph nodes, blood, and viscera, the staging system was designed to include each possible area of T-cell involvement. Each category or classification employs a label to identify the involved system so that skin = T, lymph = N, viscera or systemic metastasis = M, and blood = B. Then, each category is ranked according to the type or extent of T-cell involvement. For example, T2 = patch or plaque involving ≥ 10% of the body surface area, but the lymph nodes, viscera, and blood are not affected (see Table 4-1). The ability to correctly stage a patient is important for determining prognosis (Kim, Liu, Mraz-Gernhard, Varghese, & Hoppe, 2003). Patients diagnosed with early-stage MF have a good prognosis and typically die for reasons usually unrelated to MF. Patients with advanced-stage MF (IIB-IVB) and SS, however, are much more likely to die from their disease. Staging also serves as an effective treatment guide (Trautinger et al., 2006), which will be discussed later in this chapter.
In contrast to a host of other skin disorders both common and exotic, a diagnosis of CTCL may not be rendered until considerable time has passed or multiple investigations have taken place. Fortunately, the dermatology community has become increasingly aware of the subtle presentations of early-stage MF, thus lowering the threshold for pursuing a diagnostic workup. Patients suspected of having MF often describe a prolonged history of an indolent, pink or red, scaly, waxing and waning eruption that may be classified as eczematous dermatitis, psoriasis, or just dry skin. Because of the relatively nonspecific and mild skin signs leading to a presumptive diagnosis of eczema, a biopsy-which can provide histologic evidence for CTCL-may be delayed. Performing a skin biopsy in patients with recurrent, intractable dermatitis is critical. Symptoms of pruritus are common but do not always accompany the rash. When patients experience pruritus related to MF and SS, it ranges from mild to profoundly disruptive to both sleep and performance of daily activities.
The skin findings associated with the early patch and plaque stages of MF can diminish following outdoor ultraviolet light exposure. Hence, patients will report decreased pruritus as well as an overall improvement in the appearance of the rash during summer months. In addition to sun exposure, the lesions of MF most often prove transiently responsive to topical corticosteroid therapy, thus explaining why skin biopsy often is delayed. In fact, skin biopsies performed early in the course of MF quite frequently yield nondiagnostic results (Hymes, 2005). Pathology reports may describe a psoriasiform dermatitis or spongiotic dermatitis with only a suspicion raised for a more significant disorder such as a CTCL. Repeat skin biopsies may be required over time to confirm a diagnosis of CTCL.
Patches, plaques, tumors, and generalized erythroderma are the important descriptors for the cutaneous lesions of MF and SS. A patient who manifests more than one cutaneous feature is not unusual (Girardi et al., 2004). Disease staging and appropriate therapy largely are dependent on the accurate characterization of the observed skin findings.
Patch-stage lesions (see Figure 4-3) present as erythematous to salmon-colored, flat to slightly raised, finely scaling lesions. Regression or atrophy within the patches can produce a crinkled or cigarette paper-like appearance referred to as poikiloderma. A predisposition for covered, unexposed areas, such as the bather's trunk distribution, including breasts, hips, thighs, and buttocks, is quite common. Pruritus may accompany patch-stage lesions.
Plaques (see Figure 4-4) are erythematous, elevated lesions that can present as a single discrete lesion, multiple lesions, or coalesced larger formations. Generally, far less scaling is associated with MF plaques compared to the plaques of psoriasis. These lesions also may demonstrate small telangiectasias and varying degrees of pigmentation. Plaques may be shaped in arcuate (part of a circle) or annular (ring-like) arrangements. A predilection for skin plane cleavage lines is quite typical.
Cutaneous tumors (see Figure 4-5) are red-brown nodules (>1 cm in diameter) that elevate above the plane of the skin as dome-shaped or ulcerating lesions. In many patients, tumors may form in the absence of prior patch or plaque stage disease (referred to as de novo), so the stepwise progression of patch to plaque to tumor does not occur. In addition, certain variants of CTCL will present exclusively with tumors, and an accurate diagnosis only can be rendered with attentive patient history gathering and clinical data analysis (Willemze et al., 2005). In contrast to the earlier-stage lesions, tumors often develop on sun-exposed as well as covered areas. Ulcerating tumors may become secondarily infected and present considerable management challenges for patients. In tumors, a histologic feature known as "large-cell transformation" may carry a poorer prognosis (Girardi et al., 2004).
Erythroderma (see Figure 4-6) refers to poorly defined, generalized (> 80% body surface area) erythema on the skin of patients with MF. Erythrodermic MF can arise spontaneously or following long-term progression of patch or plaque stage disease. Patients with erythroderma are far more likely to have concurrent blood involvement than those presenting with more limited skin involvement (Girardi et al., 2004). Patients presenting with erythroderma may report heat and cold intolerance, intense pruritus, and skin pain. In erythrodermic states, diffuse exfoliation, lichenification (pronounced skin lines), and atrophy of skin surfaces are observed.
SS (see Figure 4-7) refers to the leukemic variant of MF whereby patients experience the triad of erythroderma, generalized lymphadenopathy, and presence of Sézary cells (abnormal, hyperconvoluted lymphoid cells) in the peripheral blood (Foss, 2004). The generalized erythroderma observed in SS ranges from bright red to violaceous to salmon-colored with associated leathery textural skin changes. Additional clinical findings include temperature dysregulation, keratoderma (skin thickening) of the palms and soles, alopecia, nail-plate dystrophy, and ectropion of the lower eyelids.
In SS, lymphomatous skin infiltrates are less dense because the malignant T cells traffic more readily to the peripheral blood and lymph nodes. Skin biopsies performed in this setting may be interpreted as MF or may simply reveal nonspecific histologic changes. Therefore, an evaluation of the blood to determine the presence or absence of an abnormal T-cell population has become increasingly important for establishing a diagnosis of SS. Recently, the International Society for Cutaneous Lymphoma proposed guidelines to quantify and define significant blood involvement with SS by measurements of molecular or flow-cytometric analysis (Vonderheid et al., 2002). These criteria include an absolute Sézary cell count of at least 1,000/mm3, a ratio of CD4+ T cells to CD8+ T cells of 10 or greater (e.g., a CD4:CD8 ratio of > 10:1), an increased number of circulating T cells with an aberrant expression of pan-T-cell markers, increased lymphocyte count with evidence of a T-cell clone in the blood (detected by Southern blot or polymerase chain reaction [PCR] analysis), and chromosomal abnormalities in the T-cell clone (Willemze et al., 2005).
When the burden of skin disease becomes extensive (e.g., tumors, erythroderma), the opportunity for the malignant T cells to collect and involve the blood, lymph nodes, liver, spleen, lungs, and central nervous system is increased. The lymphadenopathy typically observed in MF and SS is restricted to the more skin-draining chains. Bone marrow involvement is quite rare (Hymes, 2005).
In academic settings, dermatology and oncology disciplines often collaborate on the evaluation and treatment plan of patients with CTCL. Clinical evaluation of a suspected MF and SS diagnosis requires a history and physical examination and integration of data derived from skin biopsy, laboratory, and imaging studies. Patients are encouraged to describe the evolution of their skin lesions/rash, associated cutaneous symptoms, such as pruritus or discomfort, and responsiveness to prior therapies. Special attention should be paid to constitutional symptoms, such as fevers, chills, fatigue, weight changes, night sweats, and lymphadenopathy. Typically, patients with CTCL lack these systemic signs upon presentation. Physical examination should not only characterize and quantify the type and body surface area percentage of skin lesions but also should include a complete lymph node examination aimed at establishing the presence or absence of adenopathy in the correlating skin-draining nodes. Abdominal examination should be incorporated with palpation of the liver and spleen to determine possible enlargement.
Comprehensive and convincing histopathologic findings aid in establishing the diagnosis and further classify the disease. Performance of light microscopy of formalin-fixed, hematoxylin-eosin-stained tissue sections is the initial step in the evaluation of a suspected skin lymphoma. The ideal specimen is derived from an excisional, incisional (punch), or shave biopsy that is then formalin fixed (Fung, Murphy, Hoss, & Grant-Kels, 2002). In most cases, superficial perivascular and band-like infiltrates consisting of lymphocytes and histiocytes are present within the papillary and reticular dermis with focal projections into the epidermis.
Epidermotropism refers to the infiltration of the small to medium lymphocytes within the epidermis. Another highly specific but inconsistent feature is the intraepidermal collection of atypical lymphocytes called Pautrier microabscesses (Smoller, Santucci, Wood, & Whittaker, 2003). Immunophenotyping, which often can be performed on formalin-fixed tissue, can prove valuable. In MF, the neoplastic lymphocytes are positive for T-cell markers CD2, CD3, CD4, and CD5 and are characteristically CD7 negative. T-cell receptor gene rearrangement studies confirm clonality and are performed by either Southern blot or PCR methods. Both immunophenotyping and gene analysis studies performed on patients suspected of CTCL should be reviewed in the clinical context because false positives and negatives can occur.
Laboratory studies recommended for patients with an MF or SS diagnosis include a complete blood count with manual differential, lactate dehydrogenase, HTLV-1 antibody assay, and flow cytometry of the peripheral blood. For staging patients with IB disease or greater, a computed tomography (CT) scan of the chest, abdomen, and pelvis should be performed. With greater availability, the positron-emission tomography scan combined with CT (PET-CT) has proven to be more sensitive for detection of lymphadenopathy in advanced disease.
In keeping with the unique and often puzzling MF and SS presentations along with unpredictable course of disease, delineation of a treatment plan can present equal challenge. Planning care also includes the therapeutic aims of avoiding immunosuppression, augmenting antitumor immune response, reducing toxicities, and improving quality of life. Current therapies available to patients with a confirmed MF or SS diagnosis are intended to produce optimal clinical response rather than cure. Treatments for CTCL are broad in scope, and with this, patients may receive more than one therapy simultaneously. The aim is to reduce disease burden and postpone progression for as long as possible.
In most clinical situations, treatment of CTCL is tailored to the stage and particular features of the disease, general health concerns, and lifestyle considerations. Patients with disease limited to the skin (stages I and II) often can achieve clinical response with one of the readily available skin-directed therapies. This approach to treatment is supported by the understanding that the malignant T cells spend the majority of their time in the skin because of the homing tendencies to antigens and are dependent on the skin for survival. Thus, therapies can be delivered efficiently to the target organ, namely the skin. In contrast, patients with recalcitrant skin disease or those with demonstrated involvement of peripheral blood, lymph nodes, or visceral organs require one or more systemic therapies. In later stages of the disease, more aggressive therapies become necessary as the malignant T cells' dependence on the skin diminishes, and the disease becomes clinically established at extracutaneous sites.
Topical corticosteroids are the cornerstone of treatment for myriad skin disorders, both acute and chronic in their origins. These agents are employed as first-line treatments of MF because of ease of administration and product accessibility. Topical corticosteroids possess multiple immunomodulatory and anti-inflammatory effects by downregulation of cytokine production and promotion of inflammatory mediators (Barnes & Karin, 1997). In the early stages of the disease, topical corticosteroid therapy has proven to be a mainstay for both induction and maintenance of clinical remissions. In a prospective study of 79 patients with patch-and-plaque stage disease, daily use of topical corticosteroids for three to six months resulted in a complete response in 63% and a partial remission in 31% for a total response rate of 94% (Zackheim, Kashani-Sabet, & Amin, 1998). Topical corticosteroids are packaged in a variety of vehicle systems including creams, ointments, lotions, foams, gels, and solutions. Clinicians may recommend alternating a stronger potency (class I) agent with a less potent (class III or IV) agent over time in an effort to diminish the side-effect profile as well as to provide opportunity for longer duration of treatment. Local side effects from topical corticosteroids include skin atrophy, striae, purpura, acneform eruptions, and telangiectasias. Hypothalamic pituitary axis suppression is a very rare consequence of prolonged topical corticosteroid application.
Topical Chemotherapy: Nitrogen Mustard and Carmustine
The alkylating agents nitrogen mustard (NM) (also known as mechlorethamine) and carmustine (also known as bichloronitrosourea or BCNU) are cytotoxic chemotherapeutic agents employed for topical management of CTCL. During the past four decades, they have been used widely for the treatment of the early stages (IA, IB, and IIA) of CTCL. In 1977, Vonderheid et al. reported induction of clinical remission in 68% of patients treated with topical NM daily over the course of several months. A subsequent smaller study demonstrated an 87% complete response rate with application of NM daily (Hamminga et al., 1982).
Topical NM therapy requires thoughtful collaboration among the patient, clinician, and compounding pharmacist. A 10 mg formulation of NM is dissolved in the water, ointment, or gel base. Typically, patients apply a thin film at bedtime to all skin surfaces, excluding the eyelids, lips, and genital region. They should be advised to wash their hands with soap and water after the application process. Disposable gloves should be used if others assist with NM application.
The most frequent complication associated with NM therapy is the development of an irritant reaction characterized by local erythema and itching. This reaction can be addressed with product dilution and subsequent desensitization. Drug cessation is warranted if a true allergic reaction with urticarial response occurs. Patients with CTCL who demonstrate clinical clearing of patch-and-plaque lesions for the duration of NM therapy for 6-12 months may taper the frequency of treatments over time to a less cumbersome schedule. Less frequently encountered toxicities of NM therapy include potential for myelosuppression, reduced spermatogenesis, and secondary nonmelanoma skin cancers (Hymes, 2005).
Carmustine is available in powder and ointment forms. Local application site erythema can develop, although irritant and contact reactions occur less often. In current care practice, carmustine is rarely, if ever, selected as an alternative to NM.
Topical Retinoid: Bexarotene Gel
The synthetic retinoid agent bexarotene (Targretin®, Ligand Pharmaceuticals) selectively binds and activates retinoid X receptors (RXRs). These receptors function as transcription factors that regulate expression of genes that control cellular differentiation and proliferation. The precise mechanism of action for RXRs in the management of CTCL remains unclear. In a phase III clinical trial, Duvic, Hymes, et al. (2001) observed a 44% response rate in patients applying bexarotene gel to all lesions in early-stage refractory CTCL. Erythema, pruritus, and pain at the application site may occur in the initial weeks of therapy. For some patients, the solution to this problem may be titration of bexarotene with careful and conservative drug application ranging from every other day to two to four times daily over time. In clinical practice, the topical retinoid class of drugs is considered second-line therapy for patients who have demonstrated persistent disease after treatment with topical corticosteroids or other conservative skin-directed therapies.
Phototherapy: Broadband Ultraviolet B (290-320 nm), Narrowband UVB (311 nm), and Psoralen With UVA (320-400 nm)
Ultraviolet light therapy is one of the most widely used skin-directed therapies for early-stage CTCL. Radiation within the ultraviolet B (UVB) (290-320 nm) and UVA (320-400 nm) spectrums is prescribed for a host of T-cell-mediated skin diseases, including psoriasis, vitiligo, and cutaneous graft-versus-host disease. In early-stage MF, phototherapy is typically selected when skin involvement is diffuse and/or topical treatments have proven to be impractical. The benefits of UVA and UVB have been described for decades as the correlation between MF manifestations in covered areas of the body (e.g., bather's trunk, flanks, folds) and sparing in sun-exposed skin was observed. As mentioned previously, patients anecdotally share subjective reports of improvement in their skin during the summer months or following a tropical vacation. The mechanism of action for ultraviolet light therapy is broad with effects produced on surface membrane proteins and soluble mediators in addition to induction of apoptosis. In general, UVB reaches epidermal keratinocytes and Langerhans cells, and UVA penetrates deeper into the dermis reaching dermal fibroblasts, infiltrating inflammatory cells and dendritic cells (Krutmann & Morita, 1999).
Both broad- and narrowband UVB therapies are carried out in dermatology practices equipped with specially calibrated "light boxes." UVB therapy does not require administration of an oral sensitizing agent to produce beneficial effects in the skin. It is a reasonable choice for therapy when the lesions are thin and do not involve the hair follicle (folliculotropic MF). Patients are exposed to the UVB spectrum in a graduated fashion at increased doses with treatments taking place two to three days per week. The goal of therapy is a clinical response with an eventual taper to a more manageable schedule of one day per week. One of the major hindrances to phototherapy is the time requirement for patient visits, which may disrupt work or home life. In addition, access to a treatment center may be geographically challenging for patients who reside in rural or remote areas. Redness and burning can be problematic in certain fair-complexioned individuals; therefore, patients should be assessed prior to each treatment.
Psoralen and UVA (PUVA) phototherapy involves the combination of the photosensitizing agent 8-methoxypsoralen with UVA light. UVA radiation has a longer wavelength than UVB and can penetrate window glass and likewise can penetrate the larger and thicker lesions of MF. Patients ingest the psoralen 11/2-2 hours before exposure to an escalating dose of UVA light. Treatments are delivered three days per week initially until a maximal response is achieved. Over time, patients will reduce the frequency of treatments to a less cumbersome maintenance schedule. Toxicities of PUVA include burning, nausea related to psoralen administration, and increased risk of melanoma and nonmelanoma skin cancer. Patients are expected to wear UVA eye protection up to 24 hours following treatment because of the small but theoretical risk of cataract formation.
Radiation therapy shares a long history in the management of lymphomas, with CTCL as the first variant to be treated dating back to 1902. Photons initially were employed, but by the 1940s Trump and colleagues replaced photon-based radiation with radiation from accelerated electrons in an effort to more effectively deliver treatment to a wide field, such as the skin surface, while ensuring patient safety (Jones, Hoppe, & Glatstein, 1995). Over the past 50 years, total skin electron beam therapy (TSEBT) has undergone multiple modifications with the goal of delivering a sufficient dose to the target tissue volume while minimizing radiation damage to normal skin. The premise for electron therapy in CTCL is to produce direct toxicity to tumor cells within the target volume. Candidates for TSEBT are those patients who have extensive skin involvement of their MF lesions or have exhausted other conventional skin-directed therapies such as topical agents and phototherapy. The target volume or depth of penetration for electrons is quite minimal, approximately only 5 mm; therefore, radiation effects are produced only as deep as the dermal skin layer. Typically a total dose of 36 Gy is administered over a 9-10-week period (Voss & Kim-Sing, 1998). Some naturally shielded body areas, such as the perineum, flexural folds, and palms and soles, may require additional boost treatments for a short duration following the standard TSEBT course. Patients receiving TSEBT assume six standing positions during the course of therapy. Contact lenses, goggles, and shields for the finger- and toenail plates are placed prior to radiation exposure to ensure protection to these important structures. Patients are assessed at weekly intervals for findings of erythema, edema, bullae, or secondary infection. In some instances, treatment schedules may be interrupted for short recovery periods. The side-effect profile for TSEBT includes pruritus, dry skin, fissuring, telangiectasias, fatigue, temperature dysregulation, sun sensitivity, radiation dermatitis, skin infections, brittle nails, alopecia, and secondary malignancies. Patients are instructed throughout the course of TSEBT and for a period of time thereafter to keep the skin well hydrated with emollients such as Aquaphor® or Eucerin® (Beiersdorf, Inc.), to apply UVA/UVB-blocking sunscreens, to wear sunglasses, and to consider photo-protective garments for outdoor exposures (Reavely & Wilson, 2004) (see Figure 4-8).
Extracorporeal photopheresis (ECP) is a unique immune-modulating therapy involving the pheresis of 5%-10% of the patient's white blood cells (WBCs) and subsequent exposure to a prescribed dose of UVA light in combination with the injectable light-sensitizing agent methoxsalen. ECP may be conceptualized simply as PUVA applied to the blood rather than the skin. Once the WBC fraction is exposed to UVA light, this treated blood product is returned to the patient via peripheral or central venous access (see Figure 4-9). The mechanism of action is thought to involve an immunologic response cascade initiated by cellular apoptosis (Foss, 2006).
More than 20 years of experience with ECP as a monotherapy demonstrates that the best responders usually include immunocompetent patients with erythrodermic CTCL and early stages of SS. For immunodeficient patients and more advanced stages of SS, combination therapy of ECP plus total skin electron beam (especially for widespread plaques or tumors), interferons, and retinoids, among others, provide adjuvant boosts to debulking tumors, inducing apoptosis, and immune system stimulation (Girardi, Knobler, & Edleson, 2003). In the first clinical trial to establish efficacy in CTCL, 27 of 37 patients with refractory disease (73%) responded with improved skin scores (Edelson et al., 1987). Since that initial report, multiple studies have reported efficacy data for ECP as single or combination therapy in 438 patients with all stages of MF or SS. A compiled summary of these studies by Zic (2003) demonstrates an overall response rate of 55.7% (n = 244) and a complete response rate of 17.6%. Response definitions varied, but the minimum response criteria, where defined, was > 25% clearing of skin lesions.
ECP most often is performed on two consecutive days every month in an outpatient hospital/clinic setting at specialized treatment centers or within therapeutic apheresis units (see Figure 4-9). Accelerated therapy, administered every two weeks, may be appropriate for patients with SS or erythrodermic CTCL. Each ECP treatment averages three hours and requires adequate peripheral venous access or, as a last resort because of greatly increased risk of infection, the placement of a central venous access device (Parker & Bradley, 2006). As described for PUVA, ultraviolet light eye and skin protection are required for 24 hours after each procedure. Side effects of ECP are uncommon, mild, and transient but may include those risks associated with any venipuncture procedure, hypotension primarily in anemic or low-weight patients, exacerbation of existing congestive heart failure secondary to positive fluid balance following the procedure, and anemia associated with accelerated treatment schedules. More directly related to the reinfusion of photoactivated white blood cells, low-grade fever, increased erythema, or pruritus may occur transiently post-procedure (Therakos, Inc., 2006).
Vitamin A analogs known as retinoids are prescribed in MF and SS as single agent or in combination with other skin-directed or systemic therapies. Similar to natural vitamin A hormone, systemic retinoid agents bind to retinoid receptors in the cell and modify gene expression. Retinoid-A receptors (RARs) promote cellular differentiation and proliferation, and RXRs induce apoptosis or cell death. The nonselective RAR agonist agents isotretinoin (Accutane®, Roche Pharmaceuticals) and acitretin (Soriatane®, Stiefel Laboratories) are better known for their utility in the management of the more common skin disorders nodulocystic acne and psoriasis, respectively. However, these same agents when prescribed in MF alone or in combination with PUVA, interferons, or ECP have demonstrated significant response rates (Kim et al., 2005). RAR retinoid agents Accutane and Soriatane generally are well tolerated with some patients experiencing side effects, such as headache, arthralgia, myalgia, dry skin and lips, and sun sensitivity. Patients should be monitored for hyperlipidemia, hepatic enzyme elevation, and leukopenia.
Bexarotene (Targretin) is a synthetic RXR compound that has gained interest and use since its U.S. Food and Drug Administration (FDA) approval in 1999. Targretin in its granular, oral formulation is recommended as monotherapy or can be used in combination with other treatments in patients with MF and SS. RXR agonists act in a more selective manner than RARs by inhibiting cell growth, modulating differentiation, and inducing apoptosis in the malignant T-cell population. Targretin produces fewer subjective complaints than the RAR agents isotretinoin and acitretin. The significant risk of hypertriglyceridemia (79%) and central hypothyroidism (53%) can create an additional layer of pharmacologic complexity (Duvic, Martin, et al., 2001). Most patients are placed on HMG-CoA reductase inhibitors (statins) to correct the lipid excess and require supplemental thyroid hormone. Both RAR and RXR retinoids are teratogens and cannot be used in women who may become pregnant.
Interferons (IFNs), including IFN alfa-2b (Intron A®, Schering Corporation) and IFN gamma-1b (Actimmune®, InterMune, Inc.), represent a class of naturally occurring glycoproteins produced in response to immune system triggers. IFNs contribute to important immune regulatory functions, including stimulation of antiviral and antitumor responses (Hymes, 2005). IFNs are employed as a systemic therapy in the management of immediate stages II-B, III, and IV CTCL. In recent years, the genes for alpha, beta, and gamma IFN were cloned, paving the way for commercially available recombinant forms. IFN alfa has been studied in MF and SS for more than 20 years. IFN gamma also is used in recalcitrant MF and SS but only after patients fail IFN alfa therapy or experience significant side effects.
IFN is delivered by subcutaneous injection three times per week at dosages ranging from three to six million units. In certain situations, the frequency of injections may be reduced to once weekly (Parker & Bradley, 2006). The side-effect profile associated with IFN therapy can be quite burdensome. Flu-like symptoms, including fevers, chills, fatigue, and myalgia, frequently are time limited and can be alleviated proactively with increased fluid intake and administration of acetaminophen one hour prior to injection. Additionally, evening-hour administration of IFN therapy may diminish the experience of side effects, as patients sleep through the more bothersome ones. The more challenging and more significant side effects of IFN include depression, anxiety, sleep disturbances, gastrointestinal distress, hair loss, weight loss, increased infection risk, and elevated blood pressure. Coincident with therapy, laboratory studies, including liver enzymes and complete blood count, are assessed at regular intervals.
Denileukin diftitox (DAB IL-2, Ontak®, Ligand Pharmaceuticals) is a novel targeted therapy approved for refractory CTCL. Created with recombinant technology, this protein represents a fusion of a portion of the diphtheria toxin with IL-2 cytokine. Malignant T-cell clones express IL-2 receptor in most CTCL patients. DAB IL-2 binds to the IL-2 receptor on the lymphoma cell and is internalized with the receptor. Diphtheria toxin is released, protein synthesis is interrupted, and cell death (apoptosis) ensues. DAB IL-2 binds to the IL-2 receptor CD25+ that is identified by routine clinical immunopathology studies (Hymes, 2005). DAB IL-2 is delivered by IV infusion, typically five consecutive days in a 21-day cycle. The side-effect profile includes flu-like symptoms, fever, hypersensitivity reactions, infusion-related hypotension, hypoalbuminemia, and the more serious capillary leak syndrome. Premedicating with steroids, antihistamines, and acetaminophen dramatically can reduce the incidence of adverse events.
Vorinostat (Zolinza®, Merck & Co.) belongs to the new class of antineoplastic agents known as histone deacytylase (HDAC) inhibitors. Approved by the FDA in October 2006, the oral HDAC vorinostat is indicated for the treatment of patients with CTCL with persistent or recurrent disease following two systemic therapies. Vorinostat inhibits the enzymatic activity of HDAC 1, HDAC 2, HDAC 3, and HDAC 6. In some cancer cells, HDACs are overexpressed or an aberrant recruitment of HDACs to oncogenic transcription factors occurs. This may lead to the eventual repression of gene transcription. In vitro, HDAC inhibitors such as vorinostat cause the accumulation of acetylated histones and subsequently induce cell cycle arrest and apoptosis in the transformed cells. In an open-label, single-arm, multicenter study, the overall objective response rate was 29.7% with a median time to response of 55 days (Merck & Co., 2006). Commonly experienced side effects with vorinostat include gastrointestinal disturbances, weight loss, fatigue, chills, headache, taste alterations, increased blood creatinine, and swelling of the lower extremities. The more serious adverse events reported in clinical trials were pulmonary embolism and deep vein thrombosis, dose-related thrombocytopenia, anemia, hyperglycemia, dehydration, and QTc prolongation noted on electrocardiogram. Prior to initiation of therapy, at two-week intervals for the first two months and periodically thereafter, hematology and chemistry labs as well as electrocardiograms are monitored. Patients are encouraged to hydrate with two liters of fluid daily. Dose reductions may be necessary if patients prove intolerant to therapy (Merck & Co.) (see Figure 4-10).
Bone Marrow Transplantation
Autologous and allogeneic hemopoietic stem cell transplantation (HSCT) is reserved for advanced-staged, refractory CTCL. HSCT use for CTCL has declined since 2000, as new, more effective therapies have become available (Dearden, 2007). Optimal timing for HSCT in CTCL is unknown, and multiple factors influence the decision to transplant for MF or SS. Considerations include patient age, presence of other disease(s), performance status, response to previous systemic therapies, and availability of donor stem cells (Molina et al., 2005). Autologous transplantation has lower morbidity and mortality rates but is associated with a higher incidence of relapse (Knobler, 2004). Allogeneic transplantation is associated with more toxicity with the use of conventional chemotherapy conditioning regimens but shows lower incidence of relapse (Dearden). Allogeneic transplantation effectiveness may result from the ability to diminish patients' malignant cells and reconstitute their immune system. However, therapy can be complicated by the effects of chemo-immunoregulation or the chemo-antitumor interaction. The longer remission rates may be from the graft-versus-lymphoma effect, which is an immune-mediated response in which the engrafted donor cells attack the patient's malignant cells (lymphoma), but evidence is inconclusive (Molina et al.). HSCT for treatment of CTCL is limited, but under the right circumstances, it may be the most effective solution to an aggressive, life-threatening MF or SS.
Investigational and Future Trends
Treatment regimens for CTCL are continuously changing as new therapies emerge to replace or supplement those which have been limited in use by their toxicities, lack of disease response, or failure to affect survival. New trends in CTCL research currently target modulating disease-specific pathways of the immune system to reduce tumor burden and enhance the host response.
Vaccine Therapy: One vaccine therapy approach utilizes the clonotypic TCR peptide as a source to deliver antigenic information and stimulate antitumor CD8+ T cells (Winter et al., 2003). Enhanced dendritic cells with autologous monocytes injected into a patient's affected lymph nodes have shown promising results (Maier et al., 2003). Maier et al. suggested that this type of vaccine therapy may prove to be more effective when used with a lower tumor burden, prior to the development of immune dysregulation. Also, some beneficial effect has been shown when synthetic peptides are employed in vaccine therapy to stimulate cytotoxic CD8+ T cells (Tumenjargal et al., 2003). Although vaccine therapy for CTCL is just beginning to be explored, it does show potential as an effective treatment for MF and SS.
Cytokine Therapy: The antitumor properties of the cytokine IL-12 relate to its ability to stimulate proliferation of antigen-presenting cells and phagocytic cells, as well as to augment cytolytic T-cell and NK cell functions that are necessary to induce IFN gamma production by activated T cells (Hwang et al., 2008). IL-12, given as a subcutaneous injection or intralesionally, resulted in a significant (56%) clearing of skin lesions in patients with MF without major toxicities (Rook et al., 1999). IL-12 combined with IL-2 resulted in a synergistic effect with improved antitumor response and increased production of IL-12 (Zaki et al., 2002). IL-2 given alone had a very minor response in advanced MF and SS (Querfeld et al., 2007).
Investigational Histone Deacetylase Inhibitors
Romidepsin, previously called depsipeptide, is an HDAC inhibitor that currently is under investigation in phase II trials for CTCL. Romidepsin functions in the same manner as vorinostat, inducing cell growth arrest, cell differentiation, and apoptosis; however, its chemical structure is bicyclical and more potent (Piekarz et al., 2004). Clinical responses seen in patients with SS include decreased numbers of circulating Sézary cells, decreased incidence of erythroderma, and decreased pruritus (Piekarz et al., 2001). In a phase II international multicenter romidepsin study, promising clinical responses are being seen in patients with SS and stages IB-IVA MF. Seventeen percent of patients achieved either a complete or partial response; 30% maintained stable disease (Whittaker et al., 2006). Cardiac toxicity has been a concern and is closely monitored in the romidepsin studies. This HDAC inhibitor is not associated with myocardial damage or impaired cardiac function but does cause transient prolongation of the QTc interval despite electrolyte replacement. The safety profile for romidepsin remains under investigation (Piekarz et al., 2006). Other toxicities associated with romidepsin include nausea, fatigue, and myelosuppression.
Toll-Like Receptors: Toll-like receptors (TLRs) are immune modulators that comprise a family of molecules that act as alarms for the immune system. TLR9 is expressed by human B cells and dendritic cells. When stimulated, increasing dendritic cells are thought to enhance TH1 cytokine immune response by IFN alfa production and increased cell-mediated cytotoxicity (Krieg, 2007). These antiproliferative and pro-apoptotic properties lend themselves as arsenals to the fight against CTCL. Clinical trials using TLR9 agonists to treat advanced MF and SS showed a 25% response rate (Kim et al., 2004). However, Krieg suggested that TLRs will be more effective when used as adjuvant therapy to cancer vaccines and conventional chemotherapy.
Monoclonal Antibodies: Alemtuzumab (Campath®, Bayer Healthcare Pharmaceuticals), a human immunoglobulin G1 monoclonal antibody, targets the CD52+ cell surface proteins that are found on most neoplastic B and T cells. It is FDA approved for B-cell chronic lymphocytic leukemia and has been investigated in advanced MF and SS. In a phase II trial, Lundin et al. (2003) found an overall response rate of > 50%. Alemtuzumab was found to be especially effective for erythroderma and pruritus. Immunosuppression from the therapy led to several infections and a rare fatality, primarily in patients with advanced disease and who were heavily pretreated with other therapies. Hence, this study suggests that alemtuzumab may be more effective with less risk of infection when used at an earlier stage, before marked immunosuppression occurs.
To summarize, treatment modalities are varied and complex, and disease staging is a critical factor in deciding which treatment to institute. Treatment can range from topical steroids to investigational therapies depending on the extent of skin involvement and the presence of systemic disease. A holistic view of the patient should be considered when choosing a treatment regimen, including financial, social, and emotional concerns. The lack of effective long-term treatment remains a major problem for patients with MF and SS, with no curative therapy known to date.
Alibert, J. L. (1806). Description des maladies de la peau observées à l'Hôpital Saint-Louis et exposition des meilleurs méthodes suivies pour leur traitement
. Paris: Barrois l'aîné et fils.
Barnes, P. J., & Karin, M. (1997). Nuclear factor-kappa B: A pivotal transcription factor in chronic inflammatory diseases. New England Journal of Medicine
Chang, Y. T., Liu, H. N., Chen, C. L., & Chow, K. C. (1998). Detection of Epstein-Barr virus and HTLV-I in T-cell lymphomas of skin in Taiwan. American Journal of Dermatopathology
Clark, R. A., Chong, B. F., Mirchandani, N., Yamanaka, K., Murphy, G. F., Dowgiert, R. K., et al. (2006). A novel method for the isolation of skin resident T cells from normal and diseased human skin. Journal of Investigative Dermatology
Criscione, V. D., & Weinstock, M. A. (2007). Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Archives of Dermatology
Dearden, C. (2007). Is there a role for hemopoietic stem-cell transplantation in CTCL? Oncology
(2 Suppl. 1), 1-6.
Demierre, M. F., Gan, S., Jones, J., & Miller, D. R. (2006). Significant impact of cutaneous T-cell lymphoma on patients' quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer
Demierre, M. F., Kim, Y. H., & Zackheim, H. S. (2003). Prognosis, clinical outcomes, and quality-of-life issues in cutaneous T-cell lymphoma. Hematology/Oncology Clinics of North America
Dooms, H., Desmedt, M., Vancaeneghem, S., Rottiers, P., Goossens, V., Fiers, W., et al. (1998). Quiescence-inducing and antiapoptotic activities of IL-15 enhance secondary CD4+ T-cell responsiveness to antigen. Journal of Immunology
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., et al. (2001). Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. Journal of Clinical Oncology
Duvic, M., Martin, A. G., Kim, Y., Olsen, E., Wood, G. S., Crowley, C. A., et al. (2001). Phase II and III clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology
Edelson, R., Berger, C., Gasparro, F., Jegasothy, B., Heald, P., Wintroub, B., et al. (1987). Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. New England Journal of Medicine
Edelson, R. L. (2001). Cutaneous T-cell lymphoma: The helping hand of dendritic cells. Annals of the New York Academy of Sciences
Foss, F. (2004). Mycosis fungoides and Sézary syndrome. Current Opinion in Oncology
Foss, F. M. (2006). New insights into the mechanism of action of extracorporeal phototherapy. Transfusion
Fung, M. A., Murphy, M. J., Hoss, D. M., & Grant-Kels, J. M. (2002). Practical evaluation and management of cutaneous lymphoma. Journal of the American Academy of Dermatology
Girardi, M., Heald, P. W., & Wilson, L. D. (2004). The pathogenesis of mycosis fungoides. New England Journal of Medicine
Girardi, M., Knobler, R., & Edleson, R. (2003). Selective immunotherapy through extracorporeal photochemotherapy: Yesterday, today, and tomorrow. Hematology/Oncology Clinics of North America
Hamminga, L., Hermans, J., Noordijk, E. M., Meijer, C. J., Scheffer, E., & Van Vloten, W. A. (1982). Cutaneous T-cell lymphoma: Clinicopatholological relationships, therapy and survival in 92 patients. British Journal of Dermatology
Herne, K. L., Talpur, R., Breuer-McHam, J., Champlin, R., & Duvic, M. (2003). Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood
Hwang, S. T., Janik, J. E., Jaffe, E. S., & Wilson, W. H. (2008). Mycosis fungoides and Sézary syndrome. Lancet
Hymes, K. (2005). Cutaneous T-cell lymphomas (mycosis fungoides). In D. Rigel, R. Friedman, L. Dzubow, D. Reintgen, J.-C. Bystryn, & R. Marks (Eds.), Cancer of the skin
(pp. 349-362). Philadelphia: Saunders.
Jackow, C. M., Cather, J. C., Hearne, V., Asano, A. T., Musser, J. M., & Duvic, M. (1997). Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus,
and oligoclonal T-cell receptor V-beta gene expansion. Blood
Jones, G. W., Hoppe, R. T., & Glatstein, E. (1995). Electron beam treatment for cutaneous T-cell lymphoma. Hematology/Oncology Clinics of North America
Kim, E. J., Hess, S., Richardson, S. K., Newton, S., Showe, L. C., Benoit, B. M., et al. (2005). Immunopathogenesis and therapy of cutaneous T-cell lymphoma. Journal of Clinical Investigation
Kim, Y., Girardi, M., Duvic, M., Kuzel, T., Rook, A., Link, B., et al. (2004). TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909. Blood (ASH Annual Meeting Abstracts)
Kim, Y. H., Liu, H. L., Mraz-Gernhard, S., Varghese, A., & Hoppe, R. T. (2003). Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Archives of Dermatology
Knobler, E. (2004). Current management strategies for cutaneous T-cell lymphoma. Clinics in Dermatology
Krieg, A. M. (2007). Development of TLR9 agonists for cancer therapy. Journal of Clinical Investigation
Krutmann, J., & Morita, A. (1999). Mechanisms of ultraviolet (UV) B and UVA phototherapy. Journal of Investigative Dermatology Symposium Proceedings
Lamberg, S. I., & Bunn, P. A. Jr. (1979). Cutaneous T-cell lymphomas. Summary of the Mycosis Fungoides Cooperative Group-National Cancer Institute workshop. Archives of Dermatology
Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., et al. (2003). Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood
Lutzner, M., Edelson, R., Schein, P., Green, I., Kirkpatrick, C., & Ahmed, A. (1975). Cutaneous T-cell lymphomas: The Sézary syndrome, mycosis fungoides, and related disorders. Annals of Internal Medicine
Maier, T., Tun-Kyi, A., Tassis, A., Jungius, K. P., Burg, G., Dummer, R., et al. (2003). Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood
McCann, S. (2007). Cutaneous T-cell lymphoma: Overview and nursing perspectives. Nursing Clinics of North America
Merck & Co. (2006). Zolinza [Package insert]. Whitehouse Station, NJ: Author.
Micromedex Healthcare Series. (2007). DrugPoint
® series for hydroxyzine hydrochloride and doxepin hydrochloride.
Retrieved June 15, 2007, from http://www.thomsonhc.com
Molina, A., Zain, J., Arber, D. A., Angelopolou, M., O'Donnell, M., Murata-Collins, J., et al. (2005). Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sézary syndrome and mycosis fungoides. Journal of Clinical Oncology
National Coalition for Cancer Survivorship. (n.d.). Cancer survival toolbox
. Retrieved July 1, 2007, from http://www.cancersurvivaltoolbox.org
Ni, X., Hazarika, P., Zhang, C., Talpur, R., & Duvic, M. (2001). Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: A potential mechanism of tumor immune escape? Clinical Cancer Research
Nicol, N. H. (2003). Anatomy and physiology of the skin. In M. Hill (Ed.), Dermatology nursing essentials: A core curriculum
(2nd ed., pp. 3-16). Pitman, NJ: Dermatology Nurses' Association.
Notohamiprodjo, M., Segerer, S., Huss, R., Hildebrandt, B., Soler, D., Djafarzadeh, R., et al. (2005). CCR10 is expressed in cutaneous T-cell lymphoma. International Journal of Cancer
Parker, S. R., & Bradley, B. (2006). Treatment of cutaneous T-cell lymphoma/mycosis fungoides. Dermatology Nursing
(6), 566-570, >573-575>.
Piekarz, R. L., Frye, A. R., Wright, J. J., Steinberg, S. M., Liewehr, D. J., Rosing, D. R., et al. (2006). Cardiac studies in patients with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clinical Cancer Research
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., et al. (2001). Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood
Piekarz, R. L., Robey, R. W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A. H., et al. (2004). T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood
Querfeld, C., Rosen, S. T., Guitart, J., Rademaker, A., Foss, F., Gupta, R., et al. (2007). Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. Journal of the American Academy of Dermatology
Reavely, M. M., & Wilson, L. (2004). Total skin electron beam therapy and cutaneous T-cell lymphoma: A clinical guide for patients and staff. Dermatology Nursing
(1), 36, >39, 57>.
Rook, A. H., Wood, G. S., Yoo, E. K., Elenitsas, R., Kao, D. M., Sherman, M. L., et al. (1999). Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood
Sallusto, F., Lenig, D., Forster, R., Lipp, M., & Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature
Sézary, A., & Bouvrain, Y. (1938). Erythrodermie avec presence de cellules monstrueuses dans le derme et le sang circulant. Bulletin de la Société Française de Dermatologie et de Syphiligraphie
Smoller, B. R., Santucci, M., Wood, G. S., & Whittaker, S. J. (2003). Histopathology and genetics of cutaneous T-cell lymphoma. Hematology/Oncology Clinics of North America
Sokolowska-Wojdylo, M., Wenzel, J., Gaffal, E., Lenz, J., Speuser, P., Erdmann, S., et al. (2005). Circulating clonal CLA(+) and CD4(+) T-cells in Sézary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. British Journal of Dermatology
Therakos, Inc. (2006). Therakos photopheresis: A guide for patients and caregivers
. Exton, PA: Author.
Trautinger, F., Knobler, R., Willemze, R., Peris, K., Stadler, R., Laroche, L., et al. (2006). EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. European Journal of Cancer
Tumenjargal, S., Gellrich, S., Linnemann, T., Muche, J. M., Lukowsky, A., Audring, H., et al. (2003). Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T-cell epitope. European Journal of Immunology
Vonderheid, E. C. (2003). Treatment planning in cutaneous T-cell lymphoma. Dermatologic Therapy
Vonderheid, E. C., Bernengo, M. G., Burg, G., Duvic, M., Heald, P., Laroche, L., et al. (2002). Update on erythrodermic cutaneous T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. Journal of the American Academy of Dermatology
Vonderheid, E. C., Van Scott, E. J., Johnson, W. C., Grekin, D. A., & Asbell, S. O. (1977). Topical chemotherapy and immunotherapy of mycosis fungoides: Intermediate-term results. Archives of Dermatology
Voss, N., & Kim-Sing, C. (1998). Radiotherapy in the treatment of dermatologic malignancies. Dermatologic Clinics
Vowels, B. R., Lessin, S. R., Cassin, M., Jaworsky, C., Benoit, B., Wolfe, J. T., et al. (1994). Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. Journal of Investigative Dermatology
Whittaker, S., McCulloch, W., Robak, T., Baran, E., Prentice, A., et al. (2006). International multicenter, phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): Interim report. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I
Willemze, R., Jaffe, E. S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S. H., et al. (2005). WHO-EORTC classification for cutaneous lymphomas. Blood
Winter, D., Fiebiger, E., Meraner, P., Auer, H., Brna, C., Strohal, R., et al. (2003). Definition of TCR epitopes for CTL-mediated attack of cutaneous T-cell lymphoma. Journal of Immunology
Woetmann, A., Lovato, P., Eriksen, K. W., Krejsgaard, T., Labuda, T., Zhang, Q., et al. (2007). Nonmalignant T-cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood
Yamanaka, K., Clark, R., Dowgiert, R., Hurwitz, D., Shibata, M., Rich, B. E., et al. (2006a). Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clinical Cancer Research
Yamanaka, K., Clark, R., Rich, B., Dowgiert, R., Hirahara, K., Hurwitz, D., et al. (2006b). Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood
Yawalkar, N., Ferenczi, K., Jones, D. A., Yamanaka, K., Suh, K. Y., Sadat, S., et al. (2003). Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood
Zackheim, H. S., Kashani-Sabet, M., Amin, S. (1998). Topical corticosteroids for mycosis fungoides: Experience in 79 patients. Archives of Dermatology
Zaki, M. H., Wysocka, M., Everetts, S. E., Wang, K. S., French, L. E., Ritz, J., et al. (2002). Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: Basis for therapy of cutaneous T-cell lymphoma. Journal of Investigative Dermatology
Zic, J. A. (2003). The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatologic Therapy
Editor's Note: Many thanks to the Oncology Nursing Society (ONS) for allowing us to reprint, in 2 parts, this chapter from the book, Site-Specific Cancer Series: Skin Cancer, published by ONS. To order, call the Oncology Nursing Society toll-free at 866-257-4ONS or visit ONS online at www.ons.org. ONS Member Price: $40, Nonmember price: $60. Part 2 will appear in the March/April issue of the Journal of the Dermatology Nurses' Association.